Safety & Neglected Tropical Diseases
Together with our colleagues at the World Health Organization, the Pan American Health Organization, the NTD NGO Network (NNN), RTI International, Fred Hollows Foundation, the International Trachoma Initiative (ITI), U.S. Agency for International Development (USAID), and other organizations, we have advanced a global initiative to ensure the safety of mass drug administration (MDA) for control and elimination of neglected tropical diseases (NTDs), which reaches 1 billion people each year.
Check out key findings from our new exploratory project on Mass Drug Administration and Antimicrobial Resistance
Â
The Challenge
Â
Preventing harm to individuals while delivering health benefits to populations is an ethical responsibility of all public health programs. The medicines to prevent and control NTDs have excellent safety profiles, and MDA is a safe, effective intervention for NTD control and elimination. Although the technical components of drug safety have largely been addressed and serious adverse reactions (SAEs) such as choking rarely occur, we need to take further steps to ensure safety and fulfill the ethical mandate to ‘do no harm.’
Our Approach
Advocacy
With our collaborators, we organized workshops and participated in safety reviews to raise awareness of challenges surrounding safety and NTDs.
Research
We collaborated on research projects to better understand the incidence, risk factors, and preventive strategies for SAEs, particularly choking, during MDA for soil-transmitted helminthiasis and trachoma.
Guidance
Building on the momentum generated by advocacy and informed by research findings, we worked with partners to develop guidance and resources.
Training
To disseminate this guidance and address practical issues, FACE collaborated with several partners, including PAHO, WPRO, IZUMI Foundation, RTI and Fred Hollows Foundation on national and regional training for NTD safety in Ethiopia, Nigeria, Vanuatu, Haiti, Colombia, Dominican Republic, Paraguay, and Honduras.Â
Â
Â
Lessons Learned
Â
Advocacy: Advances in advocating for NTD safety came from linking it to the broader patient safety movement and building on the work of many partners to ensure the pharmacological safety of mass drug administrations (MDA) to prevent and control NTDs.
Research: Operational research on incidence and risk factors for choking during MDA provided the evidence base for preventive strategies. This research also revealed systemic barriers to improved NTD safety, such as weak collaboration between NTD programs and national pharmacovigilance agencies.
Guidance: Leadership by the World Health Organization, including its regional offices in Africa, the Americas, and the Western Pacific, was essential for developing normative guidance, providing training, and raising awareness.
Training: The training workshops provided a unique opportunity for frank dialogue and exchange of ideas between NTD programs and pharmacovigilance agencies, which, in many cases, set the stage for joint planning and further collaboration. Program managers in countries that had experienced SAEs were highly attuned to the need for clear communication and pharmacovigilance support, and the majority of workshops led to the development of joint NTD safety roadmaps or communiqués.
Further improvement in the safety of MDA for the control and elimination of NTDs requires:
-
Weaving safety into the culture of all MDA programs
-
Addressing programmatic aspects and capacity
-
Improved SAE reporting and investigation
-
Closer coordination between NTD programs and national pharmacovigilance agencies
-
Safety training for community drug distributors
-
More effective risk communication
Â
Resources and Tools
Â
In five short years, NTD safety has advanced significantly, building on effective advocacy, research, guidance, and training. Our NTD Safety Resources Page includes safety guidelines, educational and training materials, examples from our workshops, published research, and more.
Awareness, Planning, and Readiness
-
NTD NGO Network (NNN) Statement of Commitment to NTD Safety, September 2019.
-
Safety and NTD Master Plans: Annex 6 of the Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN) Framework for Developing Country NTD Master Plans features the importance of including safety in NTD master plans. Workshops in support of this were delivered in English and French.
-
Safety readiness assessment tools: Tools to help NTD program managers and supervisors of community drug distributors assess safety preparedness
WHO Guidance
WHO guidance document, 2021, Safety in administering medicines for neglected tropical diseases, available in English, French, Portuguese, and Spanish.
Other WHO guidance on NTD safety and adverse event management: WHO has published several guidelines and documents related to the safe administration of drugs given for NTDs, as well as guidance on assessing and reporting serious adverse events.
Assuring Safety of Preventive Chemotherapy Interventions for the Control of Neglected Tropical Diseases
Action Against Worms: Deworming Young Children
How to Add Deworming to Vitamin A Distribution
Promoting Safety of Medicines for Children
Prevention and Control of Schistosomiasis and Soil-transmitted Helminthiasis
Regional workshop on the safety of preventive chemotherapy for the elimination of neglected infectious diseases in the Region of the Americas
Neglected Infectious Diseases Safety Program — delivering community benefits while minimizing harm: Experiences and lessons learned from the Americas
Training
Peer-reviewed Publications Related to NTD Safety and Pharmacovigilance
Safe mass drug administration and trachoma elimination
An observational assessment of the safety of mass drug administration for trachoma in Ethiopian children
Safety of integrated preventive chemotherapy for neglected tropical diseases
Risk of adverse swallowing events and choking during deworming for preschool-aged children
Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study
Pharmacovigilance in low- and middle-income countries: A review with particular focus on Africa
Prevention and improved management of serious neurological adverse events during praziquantel-based mass drug administration in a Taenia solium endemic area: Experiences from Madagascar.
Other Resources on NTD Safety
Memory aides to help program managers and community drug distributors ensure all aspects required for NTD safety are in place – Annex 1 and Annex 2 of WHO document, Safety in administering medicines for neglected tropical diseases
CDD Supervisor Safety Assessment Tool for rapid field assessment of CDD safety proficiency
Guidance for safety during MDA for trachoma
Safety of co-administration of multiple drugs for several NTDsÂ
Handbook for Managing Adverse Events Following Mass Drug Administration and Serious Adverse Events. Washington, DC: USAID’s ENVISION Project, RTI-Envision; 2015.
Role-playing exercises. Role-playing exercises can be powerful learning tools to help drug distributors and program managers navigate difficult situations in which safety is potentially compromised.
NTD Workshops
To support the adoption of new safety tools and guidance developed by WHO, NGOs have collaborated with WHO, USAID, and Ministries of Health on a series of regional and national workshops. These workshops have focused on three priority areas:
1. Coordination with pharmacovigilance agencies to identify, manage, report, and prevent MDA-associated SAEs
2. Communication exercises and readiness preparation to address SAEs or rumors of adverse events
3. Prevention of MDA-associated choking-related deaths in children
The workshops included didactic sessions, small-group exercises, role-play, and group discussion. The workshop format and content were adapted to address the needs of the participants.
National workshops were held in Ethiopia, Nigeria, and Haiti in 2021 with support from USAID’s Act to End NTDs | East program. A national workshop was also hosted in Vanuatu in 2021. In June 2022, the Pan American Health Organization (PAHO), with support from IZUMI Foundation and The Fred Hollows Foundation, hosted a regional workshop for NTD Programme Managers and pharmacovigilance agencies from Colombia, the Dominican Republic, Guyana, Honduras, Nicaragua, and Paraguay.  This was followed by a Training of Trainers workshop in November 2022 and national-level Training of Trainers workshops in 2023.
Partners
World Health Organization